Who is sponsoring NCT04267887?

NCT04267887 is sponsored by OHSU Knight Cancer Institute.

What drugs are being tested in NCT04267887?

Interventions in NCT04267887: Abiraterone Acetate, Antiandrogen Therapy, Apalutamide, Prednisone, Computed Tomography, Bone Scan, Biospecimen Collection, Questionnaire Administration.

What condition does NCT04267887 study?

NCT04267887 studies Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8.

Is NCT04267887 still recruiting?

NCT04267887 is currently active, enrolled. Last updated 20 January 2026.

Last reviewed 2026-01-20 · How we verify

NCT04267887

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Active, enrolled Phase 2 Last updated 20 January 2026

What this trial tests

Phase 2 trial testing Abiraterone Acetate in Castration-Sensitive Prostate Carcinoma in 7 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

11 May 2020

Primary endpoint
1 January 2028

1 January 2030

Quick facts

Lead sponsor	OHSU Knight Cancer Institute
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	11 May 2020
Primary completion	1 January 2028
Estimated completion	1 January 2030
Sites	1 location across United States

Drugs / interventions tested

Abiraterone Acetate (ABIRATERONE) — full drug profile →
Antiandrogen Therapy — full drug profile →
Apalutamide (apalutamide) — full drug profile →
Prednisone
Computed Tomography
Bone Scan — full drug profile →
Biospecimen Collection
Questionnaire Administration

Conditions studied

Castration-Sensitive Prostate Carcinoma — all drugs for Castration-Sensitive Prostate Carcinoma →
Metastatic Prostate Carcinoma — all drugs for Metastatic Prostate Carcinoma →
Stage IVB Prostate Cancer AJCC v8 — all drugs for Stage IVB Prostate Cancer AJCC v8 →

Sponsor

OHSU Knight Cancer Institute

Who can join

18 and older, male only, with Castration-Sensitive Prostate Carcinoma or Metastatic Prostate Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well the combination of apalutamide, abiraterone acetate, and prednisone after chemotherapy work in treating patients that have received no prior treatment (treatment naive) for high risk prostate cancer that is sensitive to androgen deprivation therapy (castration sensitive) and has spread to other parts of the body (metastatic). This study also aims to understand the inheritance of prostate cancer. If a gene or genes that cause prostate cancer can be found, the diagnosis and treatment of prostate cancer may be improved. Testosterone (a male hormone) can cause the growth of prostate cancer cells. Hormone therapy using apalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells. Antihormone therapy, such as abiraterone acetate, may lessen the amount of testosterone made by the body. Anti-inflammatory drugs such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Apalutamide, abiraterone acetate, and prednisone after chemotherapy may work better in treating patients with castration sensitive prostate cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer
Castro E, Jani Y, Bilen M. · · 2026

Verify or expand the search:

Other trials of Abiraterone Acetate

Trials testing the same drug.

NCT06632977 — Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial · Phase 2 · recruiting
NCT06650579 — REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial · Phase 3 · recruiting
NCT06369610 — Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer · Phase 2 · recruiting
NCT06120491 — Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice · Phase 3 · recruiting
NCT04879589 — Phase 1 Study of ATRS-2002 in Healthy Male Adults · Phase 1 · withdrawn

Other recruiting trials for Castration-Sensitive Prostate Carcinoma

Currently open trials in the same condition.

NCT06931340 — Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati · Phase 3 · recruiting
NCT06244004 — FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, · Phase 2 · recruiting
NCT05241860 — Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Can · Phase 2 · active not recruiting
NCT04734730 — Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer · Phase 2 · recruiting

Other OHSU Knight Cancer Institute trials

Trials by the same sponsor.

NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04267887 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
Last refreshed: 20 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04267887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing